Since its introduction to clinical medicine in 1978, the fungal metabolite cyclosporin A (CyA)
has developed into the standard drug for preventing rejection of organ transplants. It also …

Examine the immunobiology of cyclosporin A. Dual features of antilymphocytic activity and
low myelotoxicity of the pharmacologically immune suppressant; Role of cyclosporin A in the …

Very little new happened in the field of immunosuppression after the discovery of
azathioprine in the early'sixties (Schwarz et al. 1959). Admittedly, there has been the …

The potential of cyclosporin A (CsA) for the immunotherapy of allograft rejection and certain
autoimmune disorders was evident in the first account by Borel et al.(1976) of the …

Cyclosporin (Cs) A (Sandimmunº) is now widely used as the immunosuppressant of choice
for preventing grafi rejection and its efficacy has also been proved in several autOimmune …

Cyclosporin A (CsA), a potent immunosuppressive agent, acts primarily by inhibiting T cell
function. Although several potential sites of action have been identified, the mechanisms …

In 1976, Borei first described the potent immunosuppressive activity of cyclosporine (CsA), a
hydrophobic, cyclic peptide of fungal origin (1). This unique immunosuppressive agent is in …

The mechanism of cyclosporin A (CS-A), a compound known to act selectively on the
immunocompetent lymphocyte, was investigated in a series of in vitro studies. CS-A …

In recent years there has been a widening gulf between the technical advances in the field
of tissue transplantation, and the development of acceptable and reliable prophylactic …

Despite the successful clinical application of the immunosuppressive drug cyclosporin A
(CsA, Sandimmun), its precise mechanism of action in the process of T cell activation …